Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TaiRxROCO:6580 +1.93%74 3-Year ROIIC % is 60.78 as of Dec. 2025, which is 1269% above its 10-year median of 4.44. GuruFocus rates ROCO:6580 with a GF Score™ of 74/100 and a GF Value™ of NT$108.31 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,320 Biotechnology companies, TaiRx ranks better than 73.64% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
TaiRx's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 60.78%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for TaiRx's 3-Year ROIIC % or its related term are showing as below:
ROCO:6580's 3-Year ROIIC % is ranked better than 73.64% of 1320
companies
in the Biotechnology industry
Industry Median: -4.835
vs ROCO:6580: 60.78
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
TaiRx 3-Year ROIIC % Related Terms
TaiRx 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for TaiRx's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6580 vs VRTX, REGN, RVMD: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, TaiRx's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiRx 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiRx's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where TaiRx's 3-Year ROIIC % falls into.
TaiRx's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -237.356 (Dec. 2025) - -213.082 (Dec. 2022) )
/
( 111.502 (Dec. 2025) - 151.437 (Dec. 2022) )
=
-24.274
/
-39.935
=
60.78%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
TaiRx (ROCO:6580) has a 3-Year ROIIC % of 60.78 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on TaiRx and its competitors. This is 1269% above median its historical median of 4.44. According to the industry distribution chart, TaiRx ranks #348 out of 1320 companies in the Biotechnology industry, placing it in the top 26.4%.
Is TaiRx's 3-Year ROIIC % too high?
TaiRx's current 3-Year ROIIC % of 60.78 is 1269% above median its 10-year median of 4.44. Based on the distribution chart, TaiRx ranks #348 out of 1320 companies in the Biotechnology industry, which is above the industry midpoint. Overall, TaiRx has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TaiRx's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiRx ranks #348 out of 1320 companies for 3-Year ROIIC %. This puts TaiRx in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on TaiRx and its competitors. TaiRx's current 3-Year ROIIC % is 60.78, which is 1269% above median its own 10-year median of 4.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiRx stock overvalued right now?
Based on GuruFocus' analysis, TaiRx (ROCO:6580) is currently considered Possible Value Trap. The stock's GF Value™ is NT$108.31, compared to a current price of NT$13.20 — trading 87.8% below its estimated fair value. The current 3-Year ROIIC % is 60.78, which is 1269% above median its 10-year median of 4.44. TaiRx's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For TaiRx (ROCO:6580), the current 3-Year ROIIC % is 60.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiRx (ROCO:6580) Overvalued in 2026?
Based on GuruFocus' analysis, TaiRx stock appears to be undervalued.
The current stock price of NT$13.20 is trading 87.8% below its estimated GF Value™ of NT$108.31.
GuruFocus considers TaiRx to be Possible Value Trap.
Key valuation signals for ROCO:6580:
3-Year ROIIC %: 60.78 (1269% above median its 10-year median of 4.44)
GF Value™: NT$108.31 vs. price of NT$13.20 (87.8% below fair value)
No single metric tells the full story. See the ROCO:6580 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiRx Inc is a pharmaceutical company based in Taiwan. It develops new drugs and improves current standard treatments to promptly find cures for diseases and fulfill unmet medical needs. The company focuses on new drug development for Asia and other markets.
74GF Score
Get the complete analysis for ROCO:6580
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6580 has been successfully added to your 
